Glioblastoma Multiforme (Treatment)

Collaboration Established To Study Thalidomide and Radiation Therapy

Published in Cancer Weekly, March 8th, 1999

Celgene Corp., Warren, New Jersey, announced a collaboration with the U.S. National Cancer Institute's (NCI) Radiation Treatment Oncology Group (RTOG), for the study of Thalomid (thalidomide) in conjunction with conventional surgery and radiation for the initial treatment of glioblastoma multiforme.

The study is designed to assess the drug's safety and efficacy in prolonging survival, and is conducted at 15 sites around the country. The study involves approximately 80 patients.

According to lead investigators, the protocol includes patients who have not previously undergone radiation therapy or chemotherapy. Following surgery, participants are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-03-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry